Clinical Trials Sponsored by Sequus Pharmaceuticals

Total 19565 results

Johnson & Johnson Pharmaceutical Research & Development...
ALZA; Sequus Pharmaceuticals

Terminated

CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Ovarian Neoplasms
Sequel Pharmaceuticals, Inc

Terminated

Effects of Intravenous K201 on the Restoration of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation (TUNDRA-AF)

Atrial Fibrillation

Denmark, Israel
Sequel Pharmaceuticals, Inc

Terminated

Phase 2 Study of Oral K201 for Prevention of AF Recurrence (ARCTIC-AF)

Atrial Fibrillation
Sequel Pharmaceuticals, Inc

Completed

Study of K201 Injection on Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation (RESTORATION)

Atrial Fibrillation

Israel, Russian Federation
Sequus Pharmaceuticals

Completed

Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

HIV Infections | Sarcoma, Kaposi

United States
Sequus Pharmaceuticals

Completed

A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma

HIV Infections | Sarcoma, Kaposi

United States
Sequus Pharmaceuticals

Completed

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

HIV Infections | Sarcoma, Kaposi

United States
Sequus Pharmaceuticals

Unknown

A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma

HIV Infections | Sarcoma, Kaposi

United States
National Institute of Allergy and Infectious Diseases...
Amgen; Sequus Pharmaceuticals

Completed

Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

HIV Infections | Sarcoma, Kaposi

United States
Seqirus

Active, not recruiting

Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying mRNA Influenza Vaccine in Healthy Adults

Influenza, Human

Australia
Seqirus

Completed

Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05

Influenza

United States, Finland
Seqirus

Completed

Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects

Virus Diseases | Influenza | Human

United States
Seqirus

Completed

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age

Influenza

Turkey, Philippines, Thailand, Malaysia, Lithuania, Colombia, Czechia, Estonia, Bulgaria, Latvia, Poland, Romania
Seqirus

Completed

Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)

Influenza

Finland, Philippines, Thailand
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza, Human

United Kingdom
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza, Human

United Kingdom
Seqirus

Completed

A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults (CSL's IVV)

Influenza

New Zealand, Australia
Seqirus

Completed

Phase II Study of Pandemic Influenza Vaccine

Influenza

Australia
Seqirus

Completed

A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

Influenza, Human

United States
Seqirus

Completed

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

Influenza, Human

United States
Seqirus

Active, not recruiting

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Influenza, Human

Philippines, United States, Germany, Pakistan, Canada, Estonia, Denmark, United Kingdom
Seqirus

Active, not recruiting

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Quadrivalent Influenza Vaccine Compared to a Non-adjuvanted Quadrivalent Influenza Vaccine in Adults ≥65 Years of Age

Influenza, Human

Turkey, Belgium, Bulgaria, Czechia, Finland, Georgia, Italy, Korea, Republic of, Lithuania, Netherlands, Poland, Romania, Spain, Taiwan
Seqirus

Completed

Flucelvax (TIVc or QIVc) Pregnancy Registry

Pregnancy | Influenza, Human | Birth Defect

United States
Seqirus

Completed

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults

Influenza

Australia, New Zealand, Philippines, South Africa
Seqirus

Completed

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Influenza, Human

United States
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

Influenza, Human

United States
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults

Influenza Caused by the Novel Influenza A (H1N1) Virus

Australia
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza, Human

United Kingdom
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

Influenza, Human

United States
Seqirus

Completed

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

Influenza

United States
Seqirus

Withdrawn

Flucelvax Pregnancy Registry

Pregnant Women, Influenza

United States
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human

United States
Seqirus

Completed

A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants

Influenza

United Kingdom
Seqirus

Completed

Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults

Influenza | Human

United States
Seqirus

Completed

A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine

Influenza, Human

Estonia, Philippines
Seqirus

Completed

Efficacy Study With QIVc in Pediatric Subjects

Influenza, Human

Bangladesh, Bulgaria, Czechia, Estonia, Honduras, Latvia, Malaysia, New Zealand, Pakistan, Philippines, Poland, Romania, Thailand, Ukraine, South Africa
Seqirus

Completed

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

Influenza, Human

United States, Estonia, Germany
Seqirus

Completed

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

Infections | RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza, Human | Orthomyxoviridae Infections | Influenza in Birds

United States
Seqirus

Completed

Afluria Pregnancy Registry

Pregnancy | Influenza, Human | Birth Defect

United States
Seqirus

Withdrawn

An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older

Influenza
Seqirus

Completed

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age

Influenza, Human

Australia, Estonia, Finland, Lithuania, Philippines, Poland, Spain, Thailand
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children

Influenza Caused by the Novel Influenza A (H1N1) Virus

Australia
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza

United Kingdom
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA

Influenza

United States
Seqirus

Completed

Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years

Influenza

Australia
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA

Influenza

United States
Seqirus

Completed

A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population

Influenza

United Kingdom
Seqirus

Completed

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

Influenza

United States
Seqirus

Completed

A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population

Influenza

Australia
Seqirus

Completed

Study of a Pandemic Influenza Vaccine in Children

Influenza

Australia

3

Subscribe